• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Sep. 12, 2018

View Archived Issues

Regulatory actions for Sept. 11, 2018

Read More

Clinical data for Sept. 11, 2018

Read More

Regulatory front

The U.S. Court of Appeals for the Eighth Circuit Monday upheld a lower court ruling that dismissed a lawsuit claiming that Amgen Inc.'s Enbrel (etanercept) caused myelodysplastic syndrome (MDS) and that imposed sanctions against the plaintiff's counsel for becoming unnecessarily argumentative and filing multiple motions that the lower court described as "barely veiled attempts to re-litigate decided issues." Read More

Other news to note

Wuxi Biologics Inc., of Shanghai, entered a partnership to manufacture protein-based therapeutics for Inhibrx Inc., of La Jolla, Calif. Under the partnership, Inhibrx will use Wuxi exclusively for any human biologic therapeutics projects that are started within the next three years. Read More

Financings

Helix Biopharma Corp., of Richmond Hill, Ontario, said it closed a private placement financing for gross proceeds of C$456,000 (US$347,082). The terms of the placement are for the purchase of units at C$1.20 each with each unit comprising one common share and one common share purchase warrant to purchase one common share at C$1.50. The company intends to use the net proceeds for working capital and research and development activities. Read More

Hearing loss programs press ahead, though many 'not ready for prime time'

Although the body of research is growing, therapeutic efforts to curb or reverse hearing loss fall far short of those in the more prominent sensory impairment of vision loss. Several dozen drugs are approved to treat visual disorders such as macular degeneration and glaucoma that can lead to blindness. In contrast, not a single drug is approved to treat or prevent hearing loss. Read More

'New era' of biochemistry: Industry gaining access to cryo-EM at U.K. facility

LONDON – The doors have opened on a U.K. industrial cryo-electron microscopy (cryo-EM) facility, making that powerful imaging technology available to companies large and small across pharma and biotech. Read More

2018 Lasker awards honor research on complexity beyond DNA

In Margaret Atwood's 1988 novel "Cat's Eye," protagonist Elaine Risley describes the freedom of being a female painter in the male-dominated art world of the 1950s (and beyond): "Since it does not matter what I do, I can do whatever I want." Read More

Oncoresponse completes $40M series B, shifting from discovery to development

Oncoresponse Inc., a company formed by Theraclone Sciences Inc. and the University of Texas MD Anderson Cancer Center to screen and discover therapeutically relevant antibodies from patients successfully treated with immunotherapy, has completed a $40 million series B equity financing. Proceeds of the round will support the advancement of five candidates into preclinical and clinical development, the Seattle-based company said. Read More

Armed with $125M, Atreca goes a-trekking deeper into antibody-based oncology therapies

When John Orwin joined Atreca Inc. in April as president and CEO, replacing co-founder Tito Serafini, who slid into the role of chief strategy officer, the stated goal was to combine Orwin's prowess in clinical scale-up with Serafini's scientific vision for the company's core Immune Repertoire Capture (IRC) technology. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 10, 2025.
  • Neuronata-R

    Corestemchemon preps US BLA filing for stem cell ALS therapy

    BioWorld
    Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated approval from the U.S. FDA, company...
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Enflonsia

    Merck wins approval FDA in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe